---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-018848"
form_type: "8-K"
ticker: "BVS"
cik: "0001665988"
company_name: "Bioventus Inc."
filed_at: "2022-07-12T23:59:59+00:00"
generated_at: "2026-06-24T16:48:06.721946+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bioventus closes CartiHeal acquisition for $315M upfront; $80M term loan funded

## Summary
- Acquired CartiHeal for ~$315M upfront plus up to $135M in sales milestone earn-outs.
- Acquisition closed July 12, 2022; $100M paid at closing, $215M deferred in tranches through 2027.
- Funded part of purchase with $80M term loan (2022-1 Term Loans) maturing Oct 29, 2026.
- Term loan bears interest at SOFR + 3.25% or Base Rate + 2.25% with leverage-based margins.
- Credit agreement amended; financial covenants include max leverage 4.75x and min interest coverage 2.25x.

## SEC filing metadata
- accession: 0001628280-22-018848
- form_type: 8-K
- ticker: BVS
- cik: 0001665988
- company_name: Bioventus Inc.
- filed_at: 2022-07-12T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1665988/000162828022018848/0001628280-22-018848-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1665988/000162828022018848/bvs-20220712.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-018848
- JSON: https://secwatch.observer/filing/0001628280-22-018848.json
- Plain text: https://secwatch.observer/filing/0001628280-22-018848.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.